267
Participants
Start Date
March 3, 2017
Primary Completion Date
February 14, 2018
Study Completion Date
February 14, 2018
Sodium Zirconium Cyclosilicate (ZS) 10g
Suspension administered 10g orally three times per day, in the first 48-hour of the study for all patients (48-hour open label initial phase)
Sodium Zirconium Cyclosilicate (ZS) 5g
Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
Sodium Zirconium Cyclosilicate (ZS) 10g
Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
Placebo
Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
Research Site, New Taipei City
Research Site, Taichung
Research Site, Hualien City
Research Site, Goyang-si
Research Site, Goyang-si
Research Site, Uijeongbu-si
Research Site, Anyang-si
Research Site, Bucheon-si
Research Site, Bucheon-si
Research Site, Hwaseong-si
Research Site, Wŏnju
Research Site, Cheongju-si
Research Site, Taichung
Research Site, Busan
Research Site, Gwangju
Research Site, Moscow
Research Site, Yaroslavl
Research Site, Saint Petersburg
Research Site, Saint Petersburg
Research Site, Yekaterinburg
Research Site, Krasnoyarsk
Research Site, Chiba
Research Site, Hanyu-shi
Research Site, Hitachi-Naka
Research Site, Ina-shi
Research Site, Kanazawa
Research Site, Koga-shi
Research Site, Matsudo-shi
Research Site, Nagoya
Research Site, Nagoya
Research Site, Shimajiri-gun
Research Site, Shizuoka
Research Site, Toride-shi
Research Site, Toyohashi
Research Site, Yakushi
Research Site, Incheon
Research Site, Incheon
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Suwon
Research Site, Taipei
Research Site, Taipei
Lead Sponsor
AstraZeneca
INDUSTRY